These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19667558)

  • 1. Management of fluoroquinolone use to avoid microbial resistance in clinical practice.
    Peterson LR
    Postgrad Med; 2001 Feb; 109(2 Suppl):51-9. PubMed ID: 19667558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From Pneumococcus to Pseudomonas: the antibacterial behaviour through the time].
    Rossolini GM
    Infez Med; 2009 Dec; 17 Suppl 5():5-12. PubMed ID: 20424531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical consequences of antimicrobial resistance.
    Rice LB
    Curr Opin Microbiol; 2009 Oct; 12(5):476-81. PubMed ID: 19716760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals.
    Rogues AM; Dumartin C; Amadéo B; Venier AG; Marty N; Parneix P; Gachie JP
    Infect Control Hosp Epidemiol; 2007 Dec; 28(12):1389-95. PubMed ID: 17994520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance--fluoroquinolones and the tiger's tail.
    Tillotson GS; Carroll J; Klugman KP
    J Chemother; 2006 Jun; 18(3):328-30. PubMed ID: 17129847
    [No Abstract]   [Full Text] [Related]  

  • 7. Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance.
    Viray M; Linkin D; Maslow JN; Stieritz DD; Carson LS; Bilker WB; Lautenbach E
    Infect Control Hosp Epidemiol; 2005 Jan; 26(1):56-62. PubMed ID: 15693409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM
    Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals.
    Karlowsky JA; Adam HJ; Desjardins M; Lagacé-Wiens PR; Hoban DJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i39-46. PubMed ID: 23587777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering.
    Bassetti M; Righi E; Pecori D; Tillotson G
    Future Microbiol; 2018 Aug; 13():1081-1094. PubMed ID: 29764190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
    Fedler KA; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):427-36. PubMed ID: 16938419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.
    Zhang Y; Li G; Liu M; You X; Feng L; Lv K; Cao J; Guo H
    Bioorg Med Chem Lett; 2011 Feb; 21(3):928-31. PubMed ID: 21232952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
    Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa.
    Zhanel GG; Hoban DJ; Schurek K; Karlowsky JA
    Int J Antimicrob Agents; 2004 Dec; 24(6):529-35. PubMed ID: 15555873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002.
    Morrissey I; Burnett R; Viljoen L; Robbins M
    J Infect; 2004 Aug; 49(2):109-14. PubMed ID: 15236917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002.
    Kern WV; Steib-Bauert M; de With K; Reuter S; Bertz H; Frank U; von Baum H
    J Antimicrob Chemother; 2005 Jan; 55(1):57-60. PubMed ID: 15574472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
    Fuller JD; Low DE
    Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate antibiotic use and why it is important: the challenges of bacterial resistance.
    Lieberman JM
    Pediatr Infect Dis J; 2003 Dec; 22(12):1143-51. PubMed ID: 14688589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.